<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01599650</url>
  </required_header>
  <id_info>
    <org_study_id>CRFB002E2402</org_study_id>
    <secondary_id>2011-002859-34</secondary_id>
    <nct_id>NCT01599650</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion</brief_title>
  <acronym>BRIGHTER</acronym>
  <official_title>A 24-month, Phase IIIb, Open-label, Randomized, Active Controlled, 3-arm, Multicenter Study Assessing the Efficacy and Safety of an Individualized, Stabilization-criteria-driven PRN Dosing Regimen With 0.5-mg Ranibizumab Intravitreal Injections Applied as Monotherapy or With Adjunctive Laser Photocoagulation in Comparison to Laser Photocoagulation in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will generate comparative data for 0.5-mg ranibizumab using PRN dosing
      administered with or without adjunctive laser treatment versus laser photocoagulation (the
      current standard of care) up to Month 6 in patients with visual impairment due to ME
      secondary to BRVO. Additionally the results of this study will provide long-term (24-month)
      safety and efficacy data for ranibizumab, administered with or without adjunctive laser
      treatment in this indication.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Visual Acuity: BCVA Change at Month 6 Compared to Baseline in Patients With Visual Impairment Due to Branch Retinal Vein Occlusion (BRVO)</measure>
    <time_frame>Baseline, 6 Months</time_frame>
    <description>Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)
-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 6 compare to Baseline, the 95% confidence interval and P value (related to the null hypothesis that this mean change is equal to zero) based on a t distribution/t test were calculated and assessed by an ANOVA model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Mean Average Change in Visual Acuity From Month 1 Through Month 24 Compared to Baseline</measure>
    <time_frame>Baseline, 24 Months</time_frame>
    <description>Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. (A positive average change from baseline of BCVA indicates improvement): Mean Average Change: for each patient, first average change is calculated as the average of the changes from baseline to Month 1 over Month 24. Then, mean average change is calculated as the average of average changes across all patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Ranibizumab Treatments From Day 1 to Month 23 by Treatment Group</measure>
    <time_frame>Day 1 through Month 23</time_frame>
    <description>Number of injections provided to the patients during the 23 month period and conducted within FAS with LOCF and observed data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Average Change in Visual Acuity (BCVA Letters) From Month 1 Through Month 6</measure>
    <time_frame>From Baseline through Month 6</time_frame>
    <description>Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters.(A positive average change from baseline of BCVA indicates improvement): Mean Average Change: for each patient, first average change is calculated as the average of the changes from baseline to Month 1 over Month 6. Then, mean average change is calculated as the average of average changes across all patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mean Change in Visual Acuity BCVA (Letters) From Baseline at Month 12 and Month 24</measure>
    <time_frame>Baseline, Month 12 and Month 24</time_frame>
    <description>Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 12 and Month 24 compare to Baseline, the 95% confidence interval and P value (related to the null hypothesis that this mean change is equal to zero) based on a t distribution/t test were calculated and were assessed by an ANOVA model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percent of Patients With a Visual Acuity Gain of ≥1, ≥5, ≥10, ≥15, and ≥30 Letters From Baseline up to Month 6 and Month 24, by Visit</measure>
    <time_frame>Baseline, Month 6 and Month 24</time_frame>
    <description>BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An increased score indicates improvement in acuity. This outcome assessed the number of participants who had improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 letters of visual acuity at Month 6 &amp; Month 24 as compared with baseline, was assessed by an ANOVA model. Endpoints related to the proportion of patients with BCVA letter gain or loss from Baseline was analyzed via stratified Cochran-Mantel-Haenszel test with stratification based on baseline BCVA (baseline BCVA less than or equal to 39, 40 to 59, greater than or equal to 60 letters, treatment groups).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With a BCVA Improvement vs Baseline or Achieving Greater Than or Equal to 73 Letters at Month 6 in the Study Eye</measure>
    <time_frame>Month 6</time_frame>
    <description>Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and Month 6 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at Month 6 indicates a positive outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With a BCVA Improvement vs Baseline or Achieved Greater Than or Equal to 73 Letters at Month 24 in the Study Eye</measure>
    <time_frame>Month 24</time_frame>
    <description>Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and Month 12 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at Month 24 indicates a positive outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mean Change in Central Reading Center-assessed Central Subfield Thickness From Month 12 and Month 24 vs. Baseline by Treatment Arm</measure>
    <time_frame>Month 12 and Month 24</time_frame>
    <description>Retinal thickness was measured using Optical Coherence Tomography (OCT). The images were reviewed by a central reading center to ensure a standardized evaluation. Stratification was done based on categories of baseline best corrected visual acuity &amp; analysis was based on analysis of variance (ANOVA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mean Change in Patient Reported Outcomes in NEI-VFQ-25 Score (Composite Score and Subscales) at Month 6 and Month 24 Compared to Baseline</measure>
    <time_frame>Months 6 and 24</time_frame>
    <description>The survey consists of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. All items are scored so that a high score represents better functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. In this format scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BCVA (Letters) Mean Average Change From First Ranibizumab Treatment to Month 24 in the Study Eye for Patients Randomized to the Laser Monotherapy Arm</measure>
    <time_frame>Month 24</time_frame>
    <description>Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)
-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 24 compare to Baseline, the 95% confidence interval and P value (related to the null hypothesis that this mean change is equal to zero) based on a t distribution/t test were calculated and assessed by an ANOVA model.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">455</enrollment>
  <condition>Branch Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>1-ranibizumab monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranibizumab 0.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-ranibizumab with laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranibizumab 0.5 mg + laser</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3-laser monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Laser monotherapy with Ranibizumab 0.5 mg from Month 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <arm_group_label>1-ranibizumab monotherapy</arm_group_label>
    <arm_group_label>2-ranibizumab with laser</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laser</intervention_name>
    <description>laser photocoagulation</description>
    <arm_group_label>2-ranibizumab with laser</arm_group_label>
    <arm_group_label>3-laser monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent must be obtained before any study assessment is performed

          -  Diagnosis of visual impairment exclusively due to ME secondary to BRVO

          -  BCVA score at Screening and Baseline between 73 and 19 letters (ETDRS)

        Exclusion Criteria:

          -  Pregnant or nursing (lactating) women

          -  Stroke or myocardial infarction less than 3 months before Screening

          -  Uncontrolled blood pressure defined as systolic value of &gt;160 mm Hg or diastolic value
             of &gt;100 mm Hg at Screening or Baseline.

          -  Any active periocular or ocular infection or inflammation at Screening or Baseline in
             either eye

          -  Uncontrolled glaucoma at Screening or Baseline or diagnosed within 6 months before
             Baseline in either eye

          -  Neovascularization of the iris or neovascular glaucoma in the study eye

          -  Use of any systemic antivascular endothelial growth factor (anti-VEGF) drugs within 6
             months before Baseline

          -  Panretinal laser photocoagulation within 3 months before Baseline or anticipated or
             scheduled within the next 3 months following Baseline in the study eye

          -  Focal or grid laser photocoagulation within 4 months before Baseline in the study eye

          -  Use of intra- or periocular corticosteroids (including sub-Tenon) within 3 months
             before Screening in the study eye

          -  Any use of intraocular corticosteroid implants (eg, dexamethasone [Ozurdex®],
             fluocinolone acetonide [Iluvien®]) in the study eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parramatta</city>
        <state>New South Wales</state>
        <zip>2150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2H0C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boisbriand</city>
        <state>Quebec</state>
        <zip>J7H 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glostrup</city>
        <zip>DK-2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dijon</city>
        <zip>21033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris cedex 10</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex 19</city>
        <zip>75940</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <state>GR</state>
        <zip>124 62</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heraklion Crete</city>
        <state>GR</state>
        <zip>711 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Larissa</city>
        <state>GR</state>
        <zip>411 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <state>GR</state>
        <zip>546 29</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Patras</city>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>GR 54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1133</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>H-1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin 7</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leiden 2333 ZA</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3011 BH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tilburg</city>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bielsko-Biala</city>
        <zip>43-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-809</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-079</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-005</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-354</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3030-163</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1050-085</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1349-019</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zilina</city>
        <state>Slovak Republic</state>
        <zip>010 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>975 17</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>826 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>851 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valladolid</city>
        <state>Castilla y Leon</state>
        <zip>47011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>L´Hospitalet de Llobregat</city>
        <state>Cataluña</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alicante</city>
        <state>Comunidad Valenciana</state>
        <zip>03016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bilbao</city>
        <state>Pais Vasco</state>
        <zip>48006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Örebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <zip>3012</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lausanne</city>
        <zip>1007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Olten</city>
        <zip>4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zuerich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frimley</city>
        <state>Surrey</state>
        <zip>GU16 7UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bristol</city>
        <zip>BS1 2LX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>NW1 5QH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plymouth</city>
        <zip>PL4 6PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2012</study_first_submitted>
  <study_first_submitted_qc>May 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2012</study_first_posted>
  <results_first_submitted>May 26, 2016</results_first_submitted>
  <results_first_submitted_qc>September 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 10, 2016</results_first_posted>
  <last_update_submitted>September 21, 2016</last_update_submitted>
  <last_update_submitted_qc>September 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Macular Edema, Branch Retinal Vein Occlusion, visual impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Vein Occlusion</mesh_term>
    <mesh_term>Vision Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1-ranibizumab Monotherapy</title>
          <description>laser therapy + Ranibizumab 0.5 mg</description>
        </group>
        <group group_id="P2">
          <title>2-ranibizumab With Laser</title>
          <description>Ranibizumab 0.5 mg + laser</description>
        </group>
        <group group_id="P3">
          <title>3-laser Monotherapy</title>
          <description>after 6 months, laser patients could be treated with ranibizumab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="180"/>
                <participants group_id="P3" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 6 Mos</title>
              <participants_list>
                <participants group_id="P1" count="174"/>
                <participants group_id="P2" count="170"/>
                <participants group_id="P3" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="161"/>
                <participants group_id="P2" count="154"/>
                <participants group_id="P3" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Administrative issue</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1-ranibizumab Monotherapy</title>
          <description>laser therapy + Ranibizumab 0.5 mg</description>
        </group>
        <group group_id="B2">
          <title>2-ranibizumab With Laser</title>
          <description>Ranibizumab 0.5 mg + laser</description>
        </group>
        <group group_id="B3">
          <title>3-laser Monotherapy</title>
          <description>after 6 months, laser patients could be treated with ranibizumab</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="183"/>
            <count group_id="B2" value="180"/>
            <count group_id="B3" value="92"/>
            <count group_id="B4" value="455"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.7" spread="10.34"/>
                    <measurement group_id="B2" value="67.3" spread="10.41"/>
                    <measurement group_id="B3" value="67.7" spread="9.67"/>
                    <measurement group_id="B4" value="66.3" spread="10.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Visual Acuity: BCVA Change at Month 6 Compared to Baseline in Patients With Visual Impairment Due to Branch Retinal Vein Occlusion (BRVO)</title>
        <description>Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)
-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 6 compare to Baseline, the 95% confidence interval and P value (related to the null hypothesis that this mean change is equal to zero) based on a t distribution/t test were calculated and assessed by an ANOVA model.</description>
        <time_frame>Baseline, 6 Months</time_frame>
        <population>analysis for change consists of the group that had a baseline and 6 month data point</population>
        <group_list>
          <group group_id="O1">
            <title>1-ranibizumab Monotherapy</title>
            <description>laser therapy + Ranibizumab 0.5 mg</description>
          </group>
          <group group_id="O2">
            <title>2-ranibizumab With Laser</title>
            <description>Ranibizumab 0.5 mg + laser</description>
          </group>
          <group group_id="O3">
            <title>3-laser Monotherapy</title>
            <description>after 6 months, laser patients could be treated with ranibizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Visual Acuity: BCVA Change at Month 6 Compared to Baseline in Patients With Visual Impairment Due to Branch Retinal Vein Occlusion (BRVO)</title>
          <description>Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)
-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 6 compare to Baseline, the 95% confidence interval and P value (related to the null hypothesis that this mean change is equal to zero) based on a t distribution/t test were calculated and assessed by an ANOVA model.</description>
          <population>analysis for change consists of the group that had a baseline and 6 month data point</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5" spread="11.78"/>
                    <measurement group_id="O2" value="56.6" spread="13.19"/>
                    <measurement group_id="O3" value="56.8" spread="13.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.3" spread="12.27"/>
                    <measurement group_id="O2" value="71.4" spread="14.43"/>
                    <measurement group_id="O3" value="62.8" spread="14.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline atMonth 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="10.70"/>
                    <measurement group_id="O2" value="14.8" spread="11.13"/>
                    <measurement group_id="O3" value="6.0" spread="14.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>difference in LS mean</param_type>
            <param_value>10.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.3</ci_lower_limit>
            <ci_upper_limit>12.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>difference in LS Means</param_type>
            <param_value>8.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.8</ci_lower_limit>
            <ci_upper_limit>11.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Average Change in Visual Acuity From Month 1 Through Month 24 Compared to Baseline</title>
        <description>Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. (A positive average change from baseline of BCVA indicates improvement): Mean Average Change: for each patient, first average change is calculated as the average of the changes from baseline to Month 1 over Month 24. Then, mean average change is calculated as the average of average changes across all patients.</description>
        <time_frame>Baseline, 24 Months</time_frame>
        <population>analysis for change consists of the group that had a baseline and 24 month data point</population>
        <group_list>
          <group group_id="O1">
            <title>1-ranibizumab Monotherapy</title>
            <description>laser therapy + Ranibizumab 0.5 mg</description>
          </group>
          <group group_id="O2">
            <title>2-ranibizumab With Laser</title>
            <description>Ranibizumab 0.5 mg + laser</description>
          </group>
          <group group_id="O3">
            <title>3-laser Monotherapy</title>
            <description>after 6 months, laser patients could be treated with ranibizumab</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Average Change in Visual Acuity From Month 1 Through Month 24 Compared to Baseline</title>
          <description>Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. (A positive average change from baseline of BCVA indicates improvement): Mean Average Change: for each patient, first average change is calculated as the average of the changes from baseline to Month 1 over Month 24. Then, mean average change is calculated as the average of average changes across all patients.</description>
          <population>analysis for change consists of the group that had a baseline and 24 month data point</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5" spread="11.78"/>
                    <measurement group_id="O2" value="56.6" spread="13.19"/>
                    <measurement group_id="O3" value="56.8" spread="13.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average Month 1 toMonth 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5" spread="12.11"/>
                    <measurement group_id="O2" value="72.0" spread="13.56"/>
                    <measurement group_id="O3" value="65.9" spread="13.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="10.86"/>
                    <measurement group_id="O2" value="15.4" spread="10.76"/>
                    <measurement group_id="O3" value="9.1" spread="13.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Ranibizumab Treatments From Day 1 to Month 23 by Treatment Group</title>
        <description>Number of injections provided to the patients during the 23 month period and conducted within FAS with LOCF and observed data.</description>
        <time_frame>Day 1 through Month 23</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-ranibizumab Monotherapy</title>
            <description>laser therapy + Ranibizumab 0.5 mg</description>
          </group>
          <group group_id="O2">
            <title>2-ranibizumab With Laser</title>
            <description>Ranibizumab 0.5 mg + laser</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Ranibizumab Treatments From Day 1 to Month 23 by Treatment Group</title>
          <description>Number of injections provided to the patients during the 23 month period and conducted within FAS with LOCF and observed data.</description>
          <units>treatments</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="5.76"/>
                    <measurement group_id="O2" value="11.3" spread="6.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Average Change in Visual Acuity (BCVA Letters) From Month 1 Through Month 6</title>
        <description>Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters.(A positive average change from baseline of BCVA indicates improvement): Mean Average Change: for each patient, first average change is calculated as the average of the changes from baseline to Month 1 over Month 6. Then, mean average change is calculated as the average of average changes across all patients.</description>
        <time_frame>From Baseline through Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-ranibizumab Monotherapy</title>
            <description>laser therapy + Ranibizumab 0.5 mg</description>
          </group>
          <group group_id="O2">
            <title>2-ranibizumab With Laser</title>
            <description>Ranibizumab 0.5 mg + laser</description>
          </group>
          <group group_id="O3">
            <title>3-laser Monotherapy</title>
            <description>after 6 months, laser patients could be treated with ranibizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Average Change in Visual Acuity (BCVA Letters) From Month 1 Through Month 6</title>
          <description>Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters.(A positive average change from baseline of BCVA indicates improvement): Mean Average Change: for each patient, first average change is calculated as the average of the changes from baseline to Month 1 over Month 6. Then, mean average change is calculated as the average of average changes across all patients.</description>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5" spread="11.78"/>
                    <measurement group_id="O2" value="56.6" spread="13.19"/>
                    <measurement group_id="O3" value="56.8" spread="13.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average Month 1 to Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7" spread="11.49"/>
                    <measurement group_id="O2" value="69.7" spread="13.38"/>
                    <measurement group_id="O3" value="61.7" spread="12.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" spread="9.60"/>
                    <measurement group_id="O2" value="13.2" spread="9.89"/>
                    <measurement group_id="O3" value="4.8" spread="11.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Change in Visual Acuity BCVA (Letters) From Baseline at Month 12 and Month 24</title>
        <description>Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 12 and Month 24 compare to Baseline, the 95% confidence interval and P value (related to the null hypothesis that this mean change is equal to zero) based on a t distribution/t test were calculated and were assessed by an ANOVA model.</description>
        <time_frame>Baseline, Month 12 and Month 24</time_frame>
        <population>Full Analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>1-ranibizumab Monotherapy</title>
            <description>laser therapy + Ranibizumab 0.5 mg</description>
          </group>
          <group group_id="O2">
            <title>2-ranibizumab With Laser</title>
            <description>Ranibizumab 0.5 mg + laser</description>
          </group>
          <group group_id="O3">
            <title>3-laser Monotherapy</title>
            <description>after 6 months, laser patients could be treated with ranibizumab</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Change in Visual Acuity BCVA (Letters) From Baseline at Month 12 and Month 24</title>
          <description>Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 12 and Month 24 compare to Baseline, the 95% confidence interval and P value (related to the null hypothesis that this mean change is equal to zero) based on a t distribution/t test were calculated and were assessed by an ANOVA model.</description>
          <population>Full Analysis set</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5" spread="11.78"/>
                    <measurement group_id="O2" value="56.6" spread="13.19"/>
                    <measurement group_id="O3" value="56.8" spread="13.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.9" spread="12.87"/>
                    <measurement group_id="O2" value="72.3" spread="15.31"/>
                    <measurement group_id="O3" value="66.8" spread="13.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" spread="12.25"/>
                    <measurement group_id="O2" value="15.7" spread="13.12"/>
                    <measurement group_id="O3" value="10.0" spread="14.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" spread="14.65"/>
                    <measurement group_id="O2" value="73.9" spread="14.59"/>
                    <measurement group_id="O3" value="68.4" spread="15.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" spread="13.91"/>
                    <measurement group_id="O2" value="17.3" spread="12.61"/>
                    <measurement group_id="O3" value="11.6" spread="16.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percent of Patients With a Visual Acuity Gain of ≥1, ≥5, ≥10, ≥15, and ≥30 Letters From Baseline up to Month 6 and Month 24, by Visit</title>
        <description>BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An increased score indicates improvement in acuity. This outcome assessed the number of participants who had improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 letters of visual acuity at Month 6 &amp; Month 24 as compared with baseline, was assessed by an ANOVA model. Endpoints related to the proportion of patients with BCVA letter gain or loss from Baseline was analyzed via stratified Cochran-Mantel-Haenszel test with stratification based on baseline BCVA (baseline BCVA less than or equal to 39, 40 to 59, greater than or equal to 60 letters, treatment groups).</description>
        <time_frame>Baseline, Month 6 and Month 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-ranibizumab Monotherapy</title>
            <description>laser therapy + Ranibizumab 0.5 mg</description>
          </group>
          <group group_id="O2">
            <title>2-ranibizumab With Laser</title>
            <description>Ranibizumab 0.5 mg + laser</description>
          </group>
          <group group_id="O3">
            <title>3-laser Monotherapy</title>
            <description>after 6 months, laser patients could be treated with ranibizumab</description>
          </group>
        </group_list>
        <measure>
          <title>The Percent of Patients With a Visual Acuity Gain of ≥1, ≥5, ≥10, ≥15, and ≥30 Letters From Baseline up to Month 6 and Month 24, by Visit</title>
          <description>BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An increased score indicates improvement in acuity. This outcome assessed the number of participants who had improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 letters of visual acuity at Month 6 &amp; Month 24 as compared with baseline, was assessed by an ANOVA model. Endpoints related to the proportion of patients with BCVA letter gain or loss from Baseline was analyzed via stratified Cochran-Mantel-Haenszel test with stratification based on baseline BCVA (baseline BCVA less than or equal to 39, 40 to 59, greater than or equal to 60 letters, treatment groups).</description>
          <units>percent patients gaining improvement</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BCVA improvement of &gt;= 1 lettermonth 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3"/>
                    <measurement group_id="O2" value="96.1"/>
                    <measurement group_id="O3" value="63.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCVA improvement of &gt;= 1 lettermonth 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.4"/>
                    <measurement group_id="O2" value="93.8"/>
                    <measurement group_id="O3" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCVA improvement of &gt;= 5 lettersmonth 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.1"/>
                    <measurement group_id="O2" value="88.2"/>
                    <measurement group_id="O3" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCVA improvement of &gt;= 5 lettersmonth 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                    <measurement group_id="O2" value="89.3"/>
                    <measurement group_id="O3" value="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCVA improvement of &gt;= 10 lettersmonth 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="68.5"/>
                    <measurement group_id="O3" value="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCVA improvement of &gt;= 10 lettersmonth 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.1"/>
                    <measurement group_id="O2" value="75.8"/>
                    <measurement group_id="O3" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCVA improvement of &gt;= 15 lettersmonth 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0"/>
                    <measurement group_id="O2" value="47.2"/>
                    <measurement group_id="O3" value="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCVA improvement of &gt;= 15 lettersmonth 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.8"/>
                    <measurement group_id="O2" value="59.6"/>
                    <measurement group_id="O3" value="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCVA improvement of &gt;= 30 lettersmonth 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                    <measurement group_id="O2" value="9.6"/>
                    <measurement group_id="O3" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCVA improvement of &gt;= 30 lettersmonth 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="14.0"/>
                    <measurement group_id="O3" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With a BCVA Improvement vs Baseline or Achieving Greater Than or Equal to 73 Letters at Month 6 in the Study Eye</title>
        <description>Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and Month 6 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at Month 6 indicates a positive outcome.</description>
        <time_frame>Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-ranibizumab Monotherapy</title>
            <description>laser therapy + Ranibizumab 0.5 mg</description>
          </group>
          <group group_id="O2">
            <title>2-ranibizumab With Laser</title>
            <description>Ranibizumab 0.5 mg + laser</description>
          </group>
          <group group_id="O3">
            <title>3-laser Monotherapy</title>
            <description>after 6 months, laser patients could be treated with ranibizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With a BCVA Improvement vs Baseline or Achieving Greater Than or Equal to 73 Letters at Month 6 in the Study Eye</title>
          <description>Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and Month 6 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at Month 6 indicates a positive outcome.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BCVA improvement of ≥ 1 letter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="171"/>
                    <measurement group_id="O3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCVA improvement of ≥ 5 letters N</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="157"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCVA improvement of ≥ 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="122"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCVA improvement of ≥ 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCVA improvement of ≥ 30 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCVA score ≥ 73 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With a BCVA Improvement vs Baseline or Achieved Greater Than or Equal to 73 Letters at Month 24 in the Study Eye</title>
        <description>Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and Month 12 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at Month 24 indicates a positive outcome.</description>
        <time_frame>Month 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-ranibizumab Monotherapy</title>
            <description>laser therapy + Ranibizumab 0.5 mg</description>
          </group>
          <group group_id="O2">
            <title>2-ranibizumab With Laser</title>
            <description>Ranibizumab 0.5 mg + laser</description>
          </group>
          <group group_id="O3">
            <title>3-laser Monotherapy</title>
            <description>after 6 months, laser patients could be treated with ranibizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With a BCVA Improvement vs Baseline or Achieved Greater Than or Equal to 73 Letters at Month 24 in the Study Eye</title>
          <description>Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and Month 12 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at Month 24 indicates a positive outcome.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BCVA improvement of ≥ 1 letter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="167"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCVA improvement of ≥ 5 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="159"/>
                    <measurement group_id="O3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCVA improvement of ≥ 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="135"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCVA improvement of ≥ 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCVA improvement of ≥ 30 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCVA score ≥ 73 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="114"/>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Change in Central Reading Center-assessed Central Subfield Thickness From Month 12 and Month 24 vs. Baseline by Treatment Arm</title>
        <description>Retinal thickness was measured using Optical Coherence Tomography (OCT). The images were reviewed by a central reading center to ensure a standardized evaluation. Stratification was done based on categories of baseline best corrected visual acuity &amp; analysis was based on analysis of variance (ANOVA)</description>
        <time_frame>Month 12 and Month 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-ranibizumab Monotherapy</title>
            <description>laser therapy + Ranibizumab 0.5 mg</description>
          </group>
          <group group_id="O2">
            <title>2-ranibizumab With Laser</title>
            <description>Ranibizumab 0.5 mg + laser</description>
          </group>
          <group group_id="O3">
            <title>3-laser Monotherapy</title>
            <description>after 6 months, laser patients could be treated with ranibizumab</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Change in Central Reading Center-assessed Central Subfield Thickness From Month 12 and Month 24 vs. Baseline by Treatment Arm</title>
          <description>Retinal thickness was measured using Optical Coherence Tomography (OCT). The images were reviewed by a central reading center to ensure a standardized evaluation. Stratification was done based on categories of baseline best corrected visual acuity &amp; analysis was based on analysis of variance (ANOVA)</description>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-215.9" spread="12.83"/>
                    <measurement group_id="O2" value="-242.5" spread="14.14"/>
                    <measurement group_id="O3" value="-203.9" spread="22.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-228.1" spread="12.65"/>
                    <measurement group_id="O2" value="-261.7" spread="15.20"/>
                    <measurement group_id="O3" value="-232.7" spread="24.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Change in Patient Reported Outcomes in NEI-VFQ-25 Score (Composite Score and Subscales) at Month 6 and Month 24 Compared to Baseline</title>
        <description>The survey consists of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. All items are scored so that a high score represents better functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. In this format scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score.</description>
        <time_frame>Months 6 and 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1-ranibizumab Monotherapy</title>
            <description>laser therapy + Ranibizumab 0.5 mg</description>
          </group>
          <group group_id="O2">
            <title>2-ranibizumab With Laser</title>
            <description>Ranibizumab 0.5 mg + laser</description>
          </group>
          <group group_id="O3">
            <title>3-laser Monotherapy</title>
            <description>after 6 months, laser patients could be treated with ranibizumab</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Change in Patient Reported Outcomes in NEI-VFQ-25 Score (Composite Score and Subscales) at Month 6 and Month 24 Compared to Baseline</title>
          <description>The survey consists of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. All items are scored so that a high score represents better functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. In this format scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>month 6 composite score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="9.56"/>
                    <measurement group_id="O2" value="4.2" spread="10.41"/>
                    <measurement group_id="O3" value="3.7" spread="12.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 24 composite score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="11.78"/>
                    <measurement group_id="O2" value="5.0" spread="11.44"/>
                    <measurement group_id="O3" value="4.9" spread="14.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BCVA (Letters) Mean Average Change From First Ranibizumab Treatment to Month 24 in the Study Eye for Patients Randomized to the Laser Monotherapy Arm</title>
        <description>Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)
-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 24 compare to Baseline, the 95% confidence interval and P value (related to the null hypothesis that this mean change is equal to zero) based on a t distribution/t test were calculated and assessed by an ANOVA model.</description>
        <time_frame>Month 24</time_frame>
        <population>Randomized set</population>
        <group_list>
          <group group_id="O1">
            <title>3- Laser Monotherapy</title>
            <description>laser therapy + Ranibizumab 0.5 mg after Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>BCVA (Letters) Mean Average Change From First Ranibizumab Treatment to Month 24 in the Study Eye for Patients Randomized to the Laser Monotherapy Arm</title>
          <description>Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)
-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 24 compare to Baseline, the 95% confidence interval and P value (related to the null hypothesis that this mean change is equal to zero) based on a t distribution/t test were calculated and assessed by an ANOVA model.</description>
          <population>Randomized set</population>
          <units>BCVA letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Value at 1st Ranibizumab treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7" spread="12.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average post 1st treatment through Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.16" spread="11.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from 1st Ranibizumab treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.49" spread="7.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>[1] Safety set was summarized based on actual treatment received. There were 3 laser monotherapy patients who received ranibizumab and 1 ranibizumab patient who received laser treatment which resulted in percentages &gt; 100% for the ranibizumab + laser arm.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ranibizumab 0.5mg</title>
          <description>Ranibizumab 0.5mg</description>
        </group>
        <group group_id="E2">
          <title>Ranibizumab 0.5mg + Laser</title>
          <description>Ranibizumab 0.5mg + Laser
[1] Safety set was summarized based on actual treatment received. There were 3 laser monotherapy patients who received ranibizumab and 1 ranibizumab patient who received laser treatment which resulted in percentages &gt; 100% for the ranibizumab + laser arm.</description>
        </group>
        <group group_id="E3">
          <title>Laser Monotherapy With Ranibizumab 0.5 mg From Month 6</title>
          <description>Laser monotherapy with Ranibizumab 0.5 mg from Month 6</description>
        </group>
        <group group_id="E4">
          <title>Laser Monotherapy Without Ranibizumab 0.5 mg From Month 6</title>
          <description>Laser monotherapy without Ranibizumab 0.5 mg from Month 6</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Coronary artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract (Fellow untreated eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cataract (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Macular fibrosis (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Macular hole (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Retinal aneurysm (Fellow untreated eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Retinopathy (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hepatic mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Perichondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Facial bones fracture (Fellow untreated eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular pressure increased (Fellow untreated eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Basal ganglia stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Burnout syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis bullous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis (Fellow untreated eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Blepharitis (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cataract (Fellow untreated eye)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cataract (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Corneal erosion (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cystoid macular oedema (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dry eye (Fellow untreated eye)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dry eye (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Eye irritation (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Eye pain (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Eye pruritus (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Eyelid oedema (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Glaucoma (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Lacrimation increased (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Macular fibrosis (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Macular oedema (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Metamorphopsia (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Ocular hypertension (Fellow untreated eye)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Ocular hypertension (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Photopsia (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Posterior capsule opacification (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Punctate keratitis (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Retinal ischaemia (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Retinal neovascularisation (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vision blurred (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vitreous adhesions (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vitreous detachment (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vitreous floaters (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Conjunctivitis (Fellow untreated eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Conjunctivitis (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Visual field defect (Fellow untreated eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Phlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Disclosure Office</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

